Effect of Intranasal Mupirocin on Rate of Staphylococcus Aureus Surgical Site Infection Following Cesarean Sections
Primary Purpose
Surgical Wound Infection, Cesarean Section, Staphylococcus Aureus
Status
Unknown status
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
Mupirocin
Sponsored by
About this trial
This is an interventional prevention trial for Surgical Wound Infection
Eligibility Criteria
Inclusion Criteria:
- Women assigned to undergo cesarean section
Exclusion Criteria:
- All others
Sites / Locations
- Hillel Yaffe Medical Center
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Intranasal Mupirocin
Arm Description
Outcomes
Primary Outcome Measures
Reduction of the incidence of surgical site infections after cesarean section
Secondary Outcome Measures
Full Information
NCT ID
NCT01152593
First Posted
May 31, 2010
Last Updated
June 28, 2010
Sponsor
Hillel Yaffe Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT01152593
Brief Title
Effect of Intranasal Mupirocin on Rate of Staphylococcus Aureus Surgical Site Infection Following Cesarean Sections
Study Type
Interventional
2. Study Status
Record Verification Date
June 2010
Overall Recruitment Status
Unknown status
Study Start Date
July 2010 (undefined)
Primary Completion Date
July 2014 (Anticipated)
Study Completion Date
December 2014 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Hillel Yaffe Medical Center
4. Oversight
5. Study Description
Brief Summary
The investigators believe that irradication of nose colonization of staphyloccocus aureus will reduce the incidence of surgical site infections after cesarean section.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Surgical Wound Infection, Cesarean Section, Staphylococcus Aureus
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
400 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Intranasal Mupirocin
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Mupirocin
Intervention Description
Intranasal cream given to patient after confirmation of colonization
Primary Outcome Measure Information:
Title
Reduction of the incidence of surgical site infections after cesarean section
Time Frame
Four years
10. Eligibility
Sex
Female
Eligibility Criteria
Inclusion Criteria:
Women assigned to undergo cesarean section
Exclusion Criteria:
All others
Facility Information:
Facility Name
Hillel Yaffe Medical Center
City
Hadera
ZIP/Postal Code
38100
Country
Israel
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gai Shrem, MD
Email
gais@hy.health.gov.il
First Name & Middle Initial & Last Name & Degree
Gai Shrem, MD
12. IPD Sharing Statement
Learn more about this trial
Effect of Intranasal Mupirocin on Rate of Staphylococcus Aureus Surgical Site Infection Following Cesarean Sections
We'll reach out to this number within 24 hrs